National Comprehensive Cancer Network
- Educational Events & Programs
- NCCN Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™
- NCCN Annual Congress: Hematologic Malignancies™
- Regional Guidelines in Oncology Symposia
- NCCN Guidelines Update Webinar Series™
- State-of-the-Art Approaches to the Treatment of NSCLC
- NCCN Academy for Excellence & Leadership in Oncology™
- NCCN Resource Tool: REMS
- NCCN CME/CE Programs
- NCCN Oncology Case Management Program™
- NCCN International Programs
Clinical Recommendations
|
|
NCCN Prevention and Treatment of Infections in Patients with Cancer Guidelines UpdateA presentation from the NCCN 12th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida, on March 17, 2007 Presenters Alison G. Freifeld, MD Brahm Segal, MD Faculty Disclosure Statements Alison G. Freifeld, MD Dr. Freifeld has disclosed that she has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in her presentation or who may financially support the educational activity. She has received honoraria from Enzon Pharmaceuticals, Inc., Merck & Co., Inc., and Schering-Plough Corporation. Dr. Freifeld has indicated that her presentation will not include discussion of investigational or unlabeled uses of a product. Brahm Segal, MD Dr. Segal has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity. He has received honoraria for his role as a speaker for Enzon Pharmaceuticals, Inc., Merck & Co., Inc., and Pfizer Inc. He has also received consulting fees for serving on an advisory committee for Pfizer Inc. and a review panel for Schering-Plough Corporation. Dr. Segal has additionally served as a paid consultant for Berlex Inc. and ViraCor Laboratories. Dr. Segal has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product. Program Overview This presentation will focus on the latest updates to the NCCN Prevention and Treatment of Infections in Patients with Cancer Guidelines and will include discussion of how to approach fever and neutropenia in patients with cancer. Prophylaxis and newer treatments associated with severe immunosuppression will also be outlined. Educational Objectives Following this activity, participants should be able to:
Intended Audience This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer. Activity Instructions Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than May 11, 2008. There is no fee for participating in this activity. Accreditation Information Physicians The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians. NCCN designates this educational activity for a maximum of 1.0 AMA PRA Category Nurses This activity is approved for 1.0 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity. Release date: May 11, 2007 Commercial Support Distribution supported by an educational grant from Amgen Oncology
|
E-mail
Print
Mark
|
|
|
|
|
|
|
||